Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218666 | 0.84 | GDA (0.34) | GDAADORA2BADORA2A | |
| Bromide SCHEMBL8165610 | 0.83 | GDA (0.33) | GDA | |
| SCHEMBL6821768 | 0.82 | GDA (0.39) | GDA | |
| SCHEMBL8843867 | 0.78 | PDE4A (0.38) | ADORA2BADORA2A | |
| SCHEMBL2940012 | 0.78 | KDM4E (0.46) | GDA | |
| SCHEMBL453204 | 0.78 | CYP1A2 (0.41) | GDAADORA2BADORA2A | |
| SCHEMBL6268075 | 0.77 | ADORA2A (0.34) | GDAADORA2BADORA2A | |
| SCHEMBL3072977 | 0.77 | MGMT (0.32) | ADORA2BADORA2A | |
| SCHEMBL6751928 | 0.77 | ADORA2B (0.35) | ADORA2BADORA2A | |
| SCHEMBL5021599 | 0.77 | ADORA2B (0.43) | ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | claimed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | claimed |
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | claimed |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | RAVIKUMAR VASULINGA T (US) | 2003-12-11 | — | — | US | claimed |
| US-6610842-B1 | Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | claimed |
| EP-1311526-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-21 | — | — | EP | claimed |
| EP-1244682-A4 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2003-02-05 | — | — | EP | claimed |
| EP-1244682-A1 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | claimed |
| US-5780607-A | PYRANOSYL NUCLEOSIDE MONOMER UNITS CONNECTED BY AMIDE LINKAGES | HOFFMANN-LA ROCHE INC. (US) | 1998-07-14 | — | — | US | claimed |
| US-5750676-A | Process for preparing nucleosides with unprotected sugars | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | claimed |
| WO-1997014709-A1 | ANTISENSE OLIGOMERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-24 | — | — | WO | claimed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| EP-0121112-B1 | 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-05-13 | — | — | EP | claimed |
| EP-0121112-A1 | 2'-Deoxy-3-phosphonylmethyl nucleosides and method for their preparation | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1984-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | PHOSPHO1, OSGEP, DTYMK | GDA 335/4885ADORA2B 2318/4885ADORA2A 1923/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | GDA 488/4885ADORA2B 848/4885ADORA2A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.